Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul Pages 1049 - 1055 ( 7 )
This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” .
Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.
Department of Gastroenterology, CHU de Saint-Etienne, 42023 Saint-Etienne, France.